Publications by authors named "Keri Mack"
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFArticle Synopsis
- Resmetirom is the first FDA-approved medication for treating nonalcoholic steatohepatitis (NASH), showing significant improvements in liver health metrics compared to placebo groups in clinical studies.
- A thorough literature search identified studies where resmetirom, dosed at 80 mg or 100 mg daily, notably improved NASH resolution and reduced liver fibrosis, highlighting its effectiveness for patients at risk of cirrhosis.
- The drug enhances treatment options for NASH patients, can be used alongside other medications, and is well tolerated, marking it as a promising choice in combination with lifestyle changes and other therapies.
Purpose: Improvement in patient outcomes from collaboration between pharmacists and physicians in ambulatory clinics has been well documented. Barriers to payment have made widespread growth of these collaborations slow. Medicare annual wellness visits (AWVs) and chronic care management (CCM) provide an opportunity for pharmacist-physician collaborations that are directly revenue generating.
View Article and Find Full Text PDF